Evaluation of the value of GATA3 combined with E-cadherin in the diagnosis of breast cancer.
To analyze the clinical value of GATA-3 combined with E-cadherin in the diagnosis of breast cancer. 120 patients with breast cancer treated in Affiliated Tumor Hospital of Guangxi Medical University for the first time (experimental group) from May 2014 to December 2016 and 80 healthy females (control group) were retrospectively analyzed. The expression levels of GATA3 and E-cadherin in the experimental group and the control group were detected by enzyme-linked immunosorbent assay (ELISA). Binary logistic regression analysis was used to evaluate the combined detection of GATA3 and E-cadherin, and the value of GATA3 and E-cadherin single diagnosis and their combined diagnosis in patients with breast cancers was compared. The expression levels of GATA3 and E-cadherin in breast cancer patients were correlated with clinical stage, human epidermal growth factor receptor 2 (HER-2), estrogen (ER) and progesterone receptor (PR) (p<0.05). The expression level of GATA3 in the experimental group was significantly higher than that in the control group (p<0.01), and the expression level of E-cadherin in the experimental group was significantly lower than that in the control group (p<0.01). GATA3 was highly expressed in breast cancer patients before surgery and decreased significantly after surgery (p<0.01). E-cadherin was lowly expressed in breast cancer patients before surgery and increased significantly after surgery (p<0.01). Combined detection of GATA3 and E-cadherin is of great significance in the diagnosis and treatment of breast cancer, and it is expected to become an effective indicator for the diagnosis of breast cancer in the future.